ILAP Performance Metrics and Innovation Passport list
Updated 24 March 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/innovative-licensing-and-access-pathway-ilap/ilap-performance-metrics-and-innovation-passport-list
ILAP Quarterly Update - March 2026
In round two, three eligible applications progressed to full assessment by the ILAP Application Review Panel. While all met the eligibility requirements, none demonstrated sufficiently strong evidence across all three selection criteria to support the award of an Innovation Passport in this round. The ILAP is committed to accelerating access to transformative new medicines. We are strengthening feedback and enhancing guidance to better support future applicants in demonstrating strong evidence across all selection criteria.
Innovation Passport metrics (as of March 2026)
| Cumulative total number of eligible applications received | 19 |
| IPs awarded | 3 |
| IPs withdrawn | 0 |
Performance metrics
| Number of IP outcomes delivered within expected timeframes | 19 out of 19 (100%) |
| Number of TDPs delivered within 6 months of IP award | 2 |
ILAP success metrics
The overarching goal of the Innovative Licensing and Access Pathway (ILAP) is to reduce the time to patient access for transformative new medicines and drug-device combinations in the UK, which will be tracked using the key success metrics set out below.
Qualitative key success measures
| Measure |
| Feedback from IP holders via surveys (including testimonials and case studies), and from the ILAP advisory groups |
Quantitative key success metrics
| Metric |
| ≥80% of IP holder survey respondents report satisfaction with ILAP |
End-to-end timelines vs “standard” for innovative medicines:
| Time (days) from MAA to final HTA final guidance for ILAP products vs non-ILAP products |
Regulatory timelines:
| Time (days) from MAA to MA grant for ILAP products vs non-ILAP products |
HTA timelines:
| Time (days) from HTA submission to first HTA final guidance for ILAP products vs non-ILAP products |
Abbreviations: MAA = Marketing Authorisation Application; MA = Market Authorisation, HTA = Health Technology Assessment
Note: First HTA final guidance is to exclude resubmissions from timelines.
Innovation Passport list
Download the latest Innovation Passport list.